Neoprobe Completes Marketing Clearances For Quantix/OR

Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it had received notification that its special 510(k) application for the revised and enhanced Quantix/OR(TM) blood flow measurement had been accepted by FDA. In addition, Neoprobe has completed the necessary regulatory steps to begin marketing the product in the EU. With the completion of the regulatory clearances, Neoprobe reintroduced the Quantix/OR at a joint meeting of the German, Austrian and Swiss cardiovascular surgical society meeting in Hamburg this past weekend. The Quantix/OR received a favorable response from the surgeons in attendance at the meeting and evaluations of the revised product have begun.

Neoprobe's Vice President of Marketing, Douglas Rash, said, "the Quantix/OR has been revised to enhance visual ergonomics and to facilitate surgeon use. The flexible probe configuration will permit surgeons to access vessels for measurement during both on- and off-pump by-pass procedures. We were pleased with the response of the physicians in Hamburg who were able to preview the product and we believe the changes that have been made to the Quantix/OR will be well received by the surgical community. Over the coming weeks, we will be working with our product distributors in the United States and Europe for a full product re-introduction at the American Association for Thoracic Surgery annual meeting in early April."